Literature DB >> 17172708

NG2/HMP proteoglycan as a cancer therapeutic target.

Martha Chekenya1, Heike Immervoll.   

Abstract

Neuroepithelial cells of the central nervous system constitute neuroglia (astrocytes, oligodendrocytes, and microglia), ependyma, and neurons, which make up the stromal cells of the brain. The stromal tissue organization of the brain is tightly regulated, but occasionally the signals that define the normal contexts become disrupted and result in cancer. Malignant progression is then maintained by cross-talks between the tumor and its stroma, where the activated stroma nurtures the proliferative and invasive neoplastic cells, by providing neovasculature, extracellular matrix components, and stimulatory growth factors. The NG2/HMP plays a major role in tumor-stroma activation through alterations in cellular adhesion, migration, proliferation, and vascular morphogenesis. Therapeutic strategies specifically targeting NG2/HMP may be useful in normalizing the tumor stroma and may reduce the toxic side effects when used in combination with conventional treatments.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17172708     DOI: 10.1385/1-59745-208-4:93

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2.

Authors:  Marta Terrile; Irene Appolloni; Filippo Calzolari; Roberto Perris; Evelina Tutucci; Paolo Malatesta
Journal:  BMC Cancer       Date:  2010-10-12       Impact factor: 4.430

Review 2.  Targeting pericytes for angiogenic therapies.

Authors:  Molly R Kelly-Goss; Rick S Sweat; Peter C Stapor; Shayn M Peirce; Walter L Murfee
Journal:  Microcirculation       Date:  2014-05       Impact factor: 2.628

3.  Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting.

Authors:  Asit K Paul; Michael J Ciesielski; Munawwar Sajjad; Xinhui Wang; Soldano Ferrone; Hani Abdel-Nabi; Robert A Fenstermaker
Journal:  J Neurooncol       Date:  2009-01-20       Impact factor: 4.130

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.